Global News Aruba 

Flex Pharma Announces Rights Dividend

BOSTON--(BUSINESS WIRE)--Flex Pharma, Inc. (Nasdaq: FLKS) announced that its Board of Directors today declared a special dividend on the Company’s common stock of one right per share of outstanding common stock. The rights will be paid on July 19, 2019 to shareholders of record as of close of business on July 18, 2019.

Flex Pharma has not listed, and does not intend to list, the rights for trading on any exchange. The terms of the rights are described in Flex Pharma’s definitive proxy statement / prospectus / information statement dated April 29, 2019 (the “Proxy Statement”), as supplemented by the Supplement dated June 27, 2019 (the “Supplement”), both of which Flex Pharma filed with the Securities and Exchange Commission.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, LLC is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company’s lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet need, with an ongoing clinical study in advanced solid tumors including, but not limited to, prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7M Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that was founded in 2014 by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate) and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology.

Additional Information and Where to Find It. This communication may be deemed to be solicitation material in respect of the proposed transaction. In connection with the proposed transaction, Flex Pharma filed with the Securities and Exchange Commission (SEC) a registration statement on Form S-4 (File No. 333-229666) containing a proxy statement / prospectus / information statement, which took effect on April 29, 2019. On April 30, 2019, Flex Pharma filed a definitive proxy statement / prospectus / information statement with the SEC. On or around May 3, 2019, Flex Pharma began mailing the definitive proxy statement / prospectus / information statement to Flex Pharma stockholders of record as of the close of business on April 17, 2019. FLEX PHARMA URGES INVESTORS AND EQUITYHOLDERS OF FLEX PHARMA AND SALARIUS TO READ THE DEFINITIVE PROXY STATEMENT / PROSPECTUS / INFORMATION STATEMENT REGARDING THE PROPOSED TRANSACTION, AS WELL AS OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT FLEX PHARMA, SALARIUS AND THE PROPOSED TRANSACTION. This communication is not a substitute for the registration statement, definitive proxy statement / prospectus / information statement or any other documents that Flex Pharma has filed or may file with the SEC or send to Flex Pharma or Salarius equityholders in connection with the proposed transaction.

You may obtain free copies of the registration statement, definitive proxy statement / prospectus / information statement, the Supplement and all other documents filed or that will be filed with the SEC regarding the proposed transaction at the website maintained by the SEC, Once they are filed, copies of the registration statement, definitive proxy statement / prospectus / information statement and the Supplement will be available free of charge on Flex Pharma’s website at or by contacting John McCabe at [email protected]

Non-Solicitation. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities in connection with the merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Forward-Looking Statements. Certain statements in this communication constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements reflect Flex Pharma’s current views about its plans. Although Flex Pharma believes that its plans as reflected in or suggested by those forward-looking statements are reasonable, it can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results will be affected by a variety of risks and uncertainties that are beyond its control. Risks and uncertainties include, but are not limited to: inability to complete the proposed transaction; and other risks and uncertainties detailed in the risk factors section of Flex Pharma’s registration statement on Form S-4 (File No. 333-229666), Form 10-K and Forms 10-Q filed with the SEC, as well as other filings Flex Pharma makes with the SEC from time-to-time. Many of these factors that will determine actual results are beyond Flex Pharma’s ability to control or predict. Flex Pharma disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


Flex Pharma, Inc.
William McVicar
Chief Executive Officer
(617) 874-1821
[email protected]

Investor Relations:
LifeSci Advisors, LLC
Jeremy Feffer
Managing Director
(212) 915-2568
[email protected]

Media Relations:
Tiberend Strategic Advisors, Inc.
Johanna Bennett
Senior Vice President
(212) 375-2686
[email protected]

Scientists at AbboMax Developed Antibodies Against PINK1 and Parkin to Study Parkinson’s Disease



A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease (PD). These phosphospecific and paired antibodies would be useful tools for studies of PINK/Parkin pathways and signaling in PD. AbboMax has been developing & manufacturing high performance immunoassay reagents for many years in California. AbboMax specializes in high-quality custom service and products focusing on antibody and assay development.

San Jose, CA, A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease. Parkinson's disease (PD) is a long-term neurodegenerative disease caused by the progressive degeneration of the dopaminergic neurons of the substantia nigra pars compacta. It is associated with a pathological process involving metabolism deregulation, protein misfolding, mitochondrial dysfunction, and neuroinflammation. PINK1 and Parkin are two genes involved in familial forms of PD through the general mechanism. PINK1 (PTEN-induced putative kinase 1, a mitochondrial kinase) and Parkin (a ubiquitin ligase) play important roles in mitochondrial quality control. PINK1provides protection against mitochondrial dysfunction during cellular stress by phosphorylating mitochondrial proteins, and is involved in the clearance of damaged mitochondria. The phosphorylation of Parkin at Ser65 in ubiquitin-like domain by PINK1 stimulates Parkin activation and translocation to damaged mitochondria where it recruits Parkin to target the organelle for degradation through autophagy. Mutations in the PINK1 protein have been shown to lead to a build-up improperly folded proteins in the mitochondria. Mutations in the serine/threonine kinase domain have been found in a number of Parkinson's patients where PINK1 fails to protect against stress-induced mitochondrial dysfunction. In our study PINK1 and Parkin were found widely expressed in nervous systems and other organs. These phosphospecific and paired antibodies would be useful tools for studies of PINK/Parkin pathways and signaling in PD. AbboMax offers: Phosphospecific PINK1 (pT257) (#630-450), Phosphospecific Parkin (pS65) (#630-420); Paired PINK1 (T257) (#630-460), Paired Parkin (S65) (#630-430); Whole protein: PINK1 (#630-470) and Parkin (#630-440).

AbboMax has been involved in researching, developing and manufacturing of high performance antibodies and related immunoassay reagents for many years. Abbomax specializes in antibody and assay development, provides high-quality custom service and products. AbboMax is focusing on phosphospecific antibodies, IHC grade monoclonal antibodies, FFPE cell pellets slides, tissue/cell blocks and CRO services including recombinant protein, custom bio-conjugation, antibody fragmentation, Antibody Epitope Mapping (AEM), scale-up process for pharmaceutical companies and CLIA labs. All the manufacturing activities are performed in the Silicon Valley Core Facility located in San Jose, California. Abbomax can provide bulk quantities at economical prices, and guarantee a fast delivery with high quality products.

Contact: Natasha Raysberg, Ph.D.
Phone 408-573-1898, Fax 408-573-1858

Unveiling the Map to Designing Treatments for Dengue and Zika Viruses



Singapore, Singapore, Scientists from the Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS), together with scientists from Duke-NUS Medical School and A*STAR’s Bioinformatics Institute (BII), have mapped out the structures of four dengue and four Zika viruses. The research focuses on understanding the genetic materials and shapes of these viruses, as well as their corresponding functions. Consequently, understanding their biology enables scientists to design better drugs and treatments.

Mosquito-borne infections are common and deadly in tropical and subtropical regions around the world. Estimates suggest up to 700 million infections and over one million deaths are caused by a variety of mosquito-borne viruses yearly. One major class of mosquito-borne viruses are the Flaviviruses, which include the dengue and Zika viruses.

Dengue is a well-known virus which affects more than 390 million people around the world. Singapore is one of the major hotspots of dengue infection[3]. Every year, 2,000 to 3,000 people are affected by dengue in Singapore[4]. Whilst most of these cases are fairly mild, dengue-associate deaths still occur each year. While the Zika virus has generally limited severity in healthy adults, there has been greater public interest due to the Zika epidemic from 2015 to 2016, and reports of adverse health effects observed in South America[5].

Using structure probing, the scientists mapped the long genetic materials of four dengue and four Zika virus strains. The research studied the viruses’ activities and vital parts to identify portions of the viruses’ genetic materials that could be targeted for treatments. Through the identification of the common shapes and structures of the viruses, scientist will be able to design new drug treatments to target these areas.

Dr Wan Yue, Principal Investigator at A*STAR’s GIS and lead author of the study, said, “One needs to understand the shape and mechanism of a lock, in order to design a key that can open it. Similarly, mapping the shapes and structures of the dengue and Zika viruses will boost understanding of their biology, and contribute significantly towards designing drug treatments targeted at these viruses.”

“Moving ahead, additional research needs to be performed to better understand how the viruses’ structural mutations reduce their effect. It will also identify the roles that different structures play during their lifecycles,” she added.

Dr Roland G. Huber, Assistant Principal Investigator at A*STAR’s BII, said, “Understanding the structures of these viruses required us to develop innovative techniques to find synergies in the vast amount of data generated for this study. We developed new tools that will allow us to better understand the architecture of these and other viruses in the future. A strong team of researchers with complementary skills enabled us to succeed.”

Professor Ng Huck Hui, Executive Director at A*STAR’s GIS, said, “The collaborative study with BII and Duke-NUS unravels significant information on the genetics of the dengue and Zika viruses. This is a crucial step towards designing targeted therapeutics to tackle the diseases.”

Digisonics Collaborates with Dr. Charles Mullins on Pediatric Cardiology Reporting Solution



Digisonics Pediatric Solution is enhanced with the most extensive library of over 300 Mullins congenital cardiology diagrams via a collaboration with world-renowned pediatric cardiologist, Dr. Charles Mullins.

Houston, TX,Digisonics is excited to announce that they have signed an exclusive agreement with Charles “Chuck” Mullins, MD, renowned pediatric cardiologist with Baylor College of Medicine and Texas Children’s Hospital. Dr. Mullins, a pioneer whose work has led to the development of new and improved techniques and devices for diagnosing and treating children and adults with congenital heart defects, is widely considered to be “the father of modern interventional pediatric cardiology.”

Dr. Mullins has granted Digisonics access to his extensive library of congenital diagrams, first published in his book "Congenital Heart Disease: A Diagrammatic Atlas," with exclusive rights to 150+ updated and new congenital diagrams. With this update, the Digisonics solution encompasses the most comprehensive collection of Mullins diagrams on the market (300+), which may be easily modified, embedded in the clinical report and used for consultations.

Associated with the new agreement, Dr. Mullins will also bring his expertise and insight to collaborate with Digisonics in the continued evolution of their solutions with the goal of becoming the gold standard for all pediatric cardiology centers. Digisonics recently released a new pediatric cath image management and reporting module, complete with hemodynamics interfaces and registry connectivity to complement the existing pediatric solution.

Recent Developments and Issues in Laser & Cosmetic Therapies Debated at the 2019 Controversies & Conversations Symposium



50+ faculty lead the discussion in San Francisco this August at a 2-day event managed by Solutions for Association Management, Inc.

Rolling Meadows, Registration for the 2019 Controversies & Conversations in Laser & Cosmetic Surgery Symposium – August 9-11 in San Francisco – is now open. The event is designed exclusively for dermatologists, laser and aesthetic surgeons, ophthalmologists, oculoplastic surgeons and other healthcare personnel.

The Symposium builds annually on its rich history with unabridged discussions on relevant topics, emerging trends and effective treatments in minimally-invasive and non-invasive aesthetic procedures. It features discussions surrounding the latest developments in new lasers, light and energy sources, skin tightening devices, injectables and other cosmetic interventions.

More than 50 leading experts are confirmed to present their views and stimulate conversation on these controversies and other emerging areas. The Symposium offers the unique opportunity to learn about and shape upcoming therapies while networking at the historic Palace Hotel.

"Thank you so much for organizing what is without question one of the best meetings in our industry. It was a privilege to be a part of it. I shared so many notes with my colleagues and encouraged them all to attend next year in San Francisco." -Anne Chapas, MD

This annual course is directed by Kenneth Arndt, MD; Jeffrey Dover, MD, FRCPC; R. Rox Anderson, MD; and Murad Alam, MD, MBA. For over 20 years they strived to prepare an event that will accommodate lively, no holds-barred discussion on the hottest topics facing the industry.

Located in downtown San Francisco, the Symposium will be held at The Palace Hotel, established in 1875 as San Francisco’s first premier luxury hotel. Step inside The Palace Hotel to be taken right back to the Gilded Age, where original architecture and authentic elements pair with classically inspired modern décor.

An early registration discount of $100 is available through May 31. To register, visit

About the Controversies & Conversations Symposium
The Controversies & Conversations Symposium, managed by Solutions for Association Management, Inc. (SAMI), is an annual educational opportunity that benefits all levels of skincare professionals interested in cutaneous and cosmetic surgery. The event offers an intimate setting to discuss and debate the latest development in lasers, devices and cosmetic procedures. For more information, visit

Follow @ControversiesMD on Twitter.
Like Skincare Controversies on Facebook.

International Standards and Guidelines for Neonatal Lung Ultrasound by a Group of International Experts from Oasis Publishers



New York, NY An international standards and Guidelines for Neonatal Lung Ultrasound titled, “Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus” was published recently in the Journal of Visualized Experiments (doi:10.3791/58990) by a group of international experts.

It was said that in the department of neonatology and NICU of Beijing Chaoyang District Maternal and Child healthcare Hospital since March 2017, chest X-rays have been replaced comprehensively by lung ultrasounds and are routinely used for the diagnosis and differential diagnosis of neonatal lung diseases. Thus, the main objective of the protocol is to popularize the application of point-of-care lung ultrasounds (POC-LUS) in neonatal intensive care units (NICUs).

According to the U.S. National Library of Medicine, an ultrasound is a type of imaging, which uses high-frequency sound waves to look at organs and structures inside the body. Since the ultrasound is the safest imaging tool, it “obviates the use of ionizing diagnostic procedures.” Due to its convenience, it has received increasing attention from neonatal physicians. However, the need to follow clear reference standards and guideline limits has been felt amongst the physicians and researcher communities.

Dr. Liujing and an international expert team observed that despite the chest x-ray being used as the main imaging tool in the diagnosis of lung diseases, yet the lung ultrasound was considered a “forbidden zone” in the detection of lung diseases. This was because ultrasonic waves are reflected when encountering air. However, utilizing artefacts formed by different pathological changes in adults, children and new-born infants challenged this understanding.

Nonetheless, the use of point-of-care lung ultrasound remains limited and to promote proper utilization of POC-LUS in the neonatal field, an international expert panel to review the latest publications on neonatal LUS was set up. The panel summarized these expert opinions and developed the present LUS protocols and guidelines for its use. Dr. Liu suggests that as a real imaging technique, LUS is user-friendly, easy to learn and easy to replicate with appropriate training.

Dr. Liujing and international expert team followed a certain protocol and the main purpose of the protocol and the guideline is to instruct users on how to use LUS to diagnose and differentiate common neonatal lung diseases. These include respiratory distress syndrome (RDS), transient tachypnoea of the new-born (TTN), pneumonia, meconium aspiration syndrome (MAS), pulmonary haemorrhage, pulmonary atelectasis and pneumothorax, etc. The normal neonatal characteristics and the LUS diagnostic criteria for different lung diseases have been described in detail in the research paper.

The team of researchers observed that POC-LUS is a feasible and convenient diagnostic method that can be performed in the neonatal intensive care unit at the bedside. Furthermore, it is a very sensitive and reliable method in the diagnosis of all types of neonatal lung diseases. Liu and the team concluded that it has multiple advantages over the chest x-ray (CXR) and/or chest computerized tomography (chest CT) scan such as accuracy, low-cost, reliability, simplicity and no risk of adverse effects due to radiation.

The guidelines have encouraged the use of LUS in the neonatal intensive care unit. However, their findings suggest that while studying the imaging modality, some issues should be considered, the details of which can be found in the research paper. According to Dr. Liujing and the team of researchers, perpendicular scanning is the most important and most commonly used scanning method. This type of scanning can also be used to examine the integrity of the diaphragm and the presence of pleural effusions.

However, the team advises that in clinical practice, LUS should not be limited to a fixed scanning sequence. Occasionally, the use of extended view function (XTD-View) can be brought about in practice. In addition to the above, Dr. Liujing and the team of researchers mention caveats. The LUS has limitations such as its being highly operator dependent and therefore the need for sufficient experience to fully understand the principles of LUS before conducting examinations. Another limitation is that some mild cases may be missed if the scan is not performed carefully. Some other limitations have been mentioned as well.

According to Liu, current literature offers well-designed, systematic and in-depth research in the area of LUS. Research findings have been validated and confirmed in clinical practice. Furthermore, Liu mentions that the protocol and guidelines followed during their research have been developed after a thorough evidence-based review of the available data by a panel of international experts in this field.

In-Depth research by Dr. Liujing and international expert team display their understanding and analytical skills in this field. Their hard work must be applauded as their research work sets a positive precedent in the field of clinical research. It can be a game changer in the medical world and can change the way point-of-care lung ultrasound diagnosis various neonatal lung diseases

Mobile Engagement Program Designed to Improve Maternal and Early Child Health and Literacy Outcomes Launches in Florida, Mississippi and New York



Asbury Park, NJ, GoMo Health, a leading population health management company, announces the launch of EduCare, an interactive program designed to promote early childhood literacy, learning, health, and wellness for families, caregivers and children ages 0-8 years old. EduCare is a market-ready program with content developed by expert health care providers, educators, and behavioral scientists.

Brain development through literacy is the most powerful tool in defining a child’s future success in school and life, and literacy development begins in the earliest months of a baby’s life, preparing them for a formal educational environment. EduCare is available to moms and caregivers, delivering age-appropriate content and activities that coincide with baby’s birth date. Content includes health and literacy resources correlated to key growth and development milestones that guide them through early childhood development.

Three initial EduCare programs, targeting moms and caregivers in their respective states, are launching in February through May 2019, with additional locations to follow:

Tallahatchie River Foundation (Mississippi)
Florida Grade-Level Reading Campaign (Florida)
Cayuga Birthplace and Family Reading Partnership (New York)

EduCare uses the GoMo Health proprietary science, BehavioralRx®, The Science of Precision Health, to build the program and determine the engagement strategy, approach and content delivered. Messages contain personalized information and resources pertaining to literacy, learning, brain development, health, and child-rearing best practices. The scientific methods and algorithms behind BehavioralRx have produced significant evidence-based improvements worldwide related to maternal and child activation measures, reporting higher outcomes for medically and behaviorally challenged family members.

“We are incredibly excited to launch the EduCare program in conjunction with these innovative leaders. Their commitment and understanding of the importance and impact of early childhood development is evident through their implementation of this lifestyle engagement program consistent with the needs of today’s parents and caregivers. In providing EduCare, they have raised the bar for childhood education on a national level,” says Bob Gold, Chief Behavioral Technologist and Founder of GoMo Health.

Learn more about EduCare at

New Hope for Old Issue: Drug Addiction and the Road to Recovery



New York, NY, April 25, 2019 

Drug addiction has been a growing and prevalent issue not only in the states but all across the globe. On average, half of medically inclined issues, crime rate, and death are associated with drug addiction and abuse. Thus, currently, the number of rehabilitation centers has been emerging one by one to assist individuals with drug addiction.

In regards to this, leading recovery institution, Addiction Center has been preparing for an extensive battle against drug dependency. They are solicitous in the welfare of their clients’ entanglement to alcohol and drug addiction. They exist for the sole reason of providing distinctive, community-based services for individuals who have addictions and other converging ailments. In addition, they give significance to a person-centered approach. Meaning, they understand and listen to your concerns, the things that are important to you, and share their seasoned proficiency to you. Through this collaborative interaction, you and your counselor can together decide on your objective and come up with strategies on how you will reach them.

This rehabilitation facility does not only center their attention to assisting individuals in their recovery, they also pay deliberation to their manpower. As an institution that delivers health care and treatment for clients, their employees, addiction specialists and counselors, staff and other medical personnel particularly adhere to a professional code of conduct.

Addiction Center imparts numerous services and assistance for people who are struggling with substance misuse, abuse, and dependence. Your mental issues and disorders are also regarded in this facility. They offer all-inclusive assessments, treatment planning, education, referrals, individual and group counseling that are designed to conform to the individual needs of their clients.

Their comprehensive treatment programs include:

Medically-monitored Detox

Inpatient and Outpatient Programs

Mental Health Services

Support Groups

Sober Living and Aftercare Program

They firmly believe that there are always second chances for those people who have the will to change. Hence, recently, they have collaborated with Dr. Darryl Gebien, a former ER doctor who wrote fake fentanyl prescriptions for his own consumption, which led to his imprisonment. Dr. Gebien admitted that he had this compulsive addiction to opioids that led him to a 2-year prison sentence. Nevertheless, he has now successfully overcome his dependency, has been freed from jail, and is presently working with Addiction Center as a living testimony that anyone can attain sobriety.

If you wish to see more of the inspiring story, experience, and journey of Dr. Gebien and all the whereabouts of drug addiction, you can access their YouTube channel at You can also find them on Twitter at You can learn more about substance abuse and gain insights and caring advisory by calling their 24/7 addiction helpline at 1 800-615-1067.

Addiction Center is your source of information about addiction treatment and any inquiries and questions you have regarding drug rehabilitation. They help reduce the adverse effects of drug abuse and addiction through sharing informative and excellent videos that will enlighten you on proper harm reduction and effective drug addiction treatment.

SFATA Uncovers an Epidemic of Misinformation About Vaping



Washington, DC, April 25, 2019 --- There’s an epidemic of misinformation about vaping in the United States. SFATA, the Smoke Free Alternatives Trade Association, wants to make sure you’re getting the truth – not just the fake facts.

SFATA believes that while the FDA is busy giving adults and teens an epidemic of misinformation, Public Health England, the national health organization of the UK, has truthful data showing that "vaping may be contributing to 20,000 UK smokers quitting every year" – and that about "40% of smokers in the UK still haven’t tried vaping," which means there are a lot more future quitters out there. Source: Public Health England, 2018

Here are 2 truths and no lies from studies done in the UK:

1. "Vaping is at least 95% less harmful than smoking." Source: Public Health England, 2018
2. "There is no evidence that second-hand vapor harms those around you." Cancer Research UK, 2016.

Here are facts about SFATA so you understand who we are:

We’ve been on record - in our mission statement, in our bylaws and in how each of our hundreds of members conduct business while adhering to our strict Code of Conduct, that we simply will not sell to anyone under the Legal adult age.

We’ve strengthened our position by signing on with IntellicheckTM, so that each of our member businesses can run customer IDs through their advanced Age Authentication system to verify identity and age.

We don’t want kids – not yours, not ours, not any, to vape. Our member businesses never did and never will sell to them.

What we do want is to allow adults who are benefitting from the harm-reduction of vaping to continue to patronize the vapor retailers of their choice; the entrepreneurs and local community businesses staffed by knowledgeable vapor professionals. Most are in the vapor community because vaping has helped them give up their own tobacco smoking habits.

About SFATA: SFATA is the premier and largest vapor and e-cig trade association. The association represents the interests of the entire supply chain, including manufacturers, online retailers, brick and mortar vapor store, distributors, importers, and wholesalers. For more information about SFATA, visit and follow SFATA on Facebook, Twitter, and Instagram.

SFATA Executive Director: Mark Anton, (973) 252-4326
SFATA Media and Public Relations: Amy Krakow, 212-587-0540

Nutritional Deficiency Should be Addressed at a Young Age



Nutritional Deficiency Should be Addressed at a Young Age
Inadequacy of vitamins and minerals can directly hamper the immune system.

New Delhi, India, April 25, 2019  As per a new study titled, "Inadequate zinc intake in India: past, present and future," rising carbon dioxide levels can accelerate zinc deficiency in crops and thus in human consumption. It states that inadequate zinc intake has been rising in India for decades, causing tens of millions of people to become newly deficient in it. The highest rate of inadequate zinc intake is concentrated mainly in the southern and northeastern states with rice-dominated diets: Kerala, Tamil Nadu, Andhra Pradesh, Manipur and Meghalaya.

Zinc has a critical role to play in the human immune system. Inadequate levels of zinc can result in serious health consequences, particularly in young children, who are more susceptible to malaria, diarrheal diseases, and pneumonia.

Speaking about this, Padma Shri Awardee, Dr KK Aggarwal, President, HCFI, said, “Micronutrient deficiencies or deficiencies of vitamins and minerals, often referred to as hidden hunger mainly due to diets inadequate in fruits and vegetables as well as whole grains and millets, are not apparent but considered ubiquitous. The primary reason for this deficiency is the availability of foods rich in carbs, sugars and fats, but lacking in vital vitamins and minerals. This is also aggravated by the fact that the consumption of junk food is increasing among educated, wealthier households in India. Although any individual can experience micronutrient deficiency, pregnant women and children are at greatest risk of developing deficiencies.”

NIN recommends consumption of 400 grams of fruit and vegetable per day for normal people, of which 100 grams should be fruit. Fruits and vegetables are rich sources of micronutrients and egg, milk as well as flesh foods are also good sources.

Adding further, Dr Aggarwal, who is also the Group Editor-in-Chief of IJCP, said, “Even home-cooked food can be deficient in nutrients. This is because we tend to cook and over-cook a lot of dishes as part of their preparation. Micronutrient deficiency is an issue that does not have an easy solution. The best way out is to get maximum nutrition from raw fruits and vegetables and forego a processed food diet.”

Schools can help in shaping the lives of students and have a very important role to play in the battle against nutritional deficiencies. Healthy habits in childhood lay a foundation for a healthier adulthood. Some helpful habits entail eating a healthy balanced diet. All the four major food groups including carbohydrates, proteins, fats, and dairy should form a part of a child’s diet plan.

Some rich sources of zinc
· For those who consume non-vegetarian food, fish is an excellent source of zinc. Meat and poultry are other options. Eggs also contain a good amount of zinc.
· For vegetarians, the best options include a handful of nuts in their daily diet. These can be a mix of walnuts, almonds, cashews and other dry fruits and nuts.
· Other food items to supplement daily zinc requirement include legumes, whole grains and dairy products.

HCA/HealthONE’s Presbyterian/St. Luke’s Medical Center and Rocky Mountain Hospital for Children Physician Offers Robotic Procedures for Adolescent & Pediatric Patients



Denver, CO, April 16, 2019  Presbyterian/St. Luke’s Medical Center and Rocky Mountain Hospital for Children are proud to offer adolescent and pediatric robotic procedures for the following conditions: Appendectomy, Intestinal resection, Choledochal Cyst, Cholecystectomy, Splenectomy, Partial Splenectomy, Adrenalectomy, Nissen Fundoplication, Heller Myotomy, Pyloroplasty, Intestinal Resection, Ileostomy, Colon Resection, Colectomy with Pull Through, Correction of Malrotation and Ovarian Cyst Removal.

Dr. Kristin Shipman, pediatric surgeon and the only physician using the da Vinci® Xi robot for pediatric and adult procedures in Colorado, states, “There are many benefits to using the robot on pediatric and adolescent patients for these procedures including: shorter hospital stays, decreased blood loss, decreased pain, quicker return to work, smaller incisions, improved cosmetic appearance, decreased operative times and a decreased likelihood of mortality.”

In 2003, Presbyterian/St. Luke’s was the first hospital in the Rocky Mountain Region to acquire a robot, obtaining the da Vinci® Si. Today, P/SL is one of the largest robotic programs in the region offering robotic procedures for: Colorectal, ENT, Gallbladder, General, Hernia Repair, Hysterectomy, Nephrectomy, Prostatectomy, Sacrocolpopexy for Pelvic Prolapse and Single-Site Surgery.

For more information on pediatric services at Rocky Mountain Hospital for Children, please visit For more information about adult robotic services, please visit Presbyterian/St. Luke’s Medical Center at

About HCA/HealthONE’s Presbyterian/St. Luke’s Medical Center
For more than 135 years, Presbyterian/St. Luke’s Medical Center (P/SL) has been meeting the healthcare needs of patients and their families from across the Rocky Mountain and Great Plains regions, and from around the world. With more than 80 specialties, 1,200 specialists and primary care physicians and 1,800 employees, P/SL and Rocky Mountain Hospital for Children is the only tertiary/quaternary combined pediatric and adult hospital in this region. Leading comprehensive services include the Center for Minimally Invasive Surgery, Cardiovascular Services, Cancer Care, Blood & Marrow Transplant, Labor & Delivery/Mom & Baby, Maternal-Fetal Care, Orthopedics, Spine, Kidney/Liver Transplant, Hyperbaric Medicine, Wound Healing, Infectious Disease and more. For more information, please visit

About HealthONE’s Rocky Mountain Hospital for Children at P/SL
Rocky Mountain Hospital for Children at P/SL is a dedicated pediatric hospital and the anchor facility for HealthONE’s system of pediatric care. With more than 300 board-certified pediatric specialists and sub-specialists, RMHC has the largest Level IV Neonatal Intensive Care Unit (NICU) in the Rocky Mountain region, the most experienced high-risk maternal fetal program, a world-renowned specialized center for minimally invasive surgery for infants and children and a nationally renowned institute for youth sports medicine, including a center focused on concussion. RMHC has 9 Denver-area locations and two dedicated pediatric ERs. For more information, please visit

Dr. Varkarakis, Board Certified Plastic and Craniofacial Surgeon Discusses New Technique to Address Aging in the Face



Miami, FL, April 16, 2019 Using the Browlift with an upper eyelid incision to address aging in the upper face

With aging, the soft tissues of the face lose the support from the brow and the eye brow takes a lower position. Also with the excess skin of the eyelid, the goal is normally try to lift up our eye brows in order to see better. That leads to chronic writings on the forehead and also lateral hooding on the lateral sides. That, with the loss of subcutaneous fat from the forehead produces the chronic aging signs of the upper forehead which is known as lateral hooding and brow optosis as well as excess eyelid skin. To repair that, there are several options, either chemical denervation of the muscles in order to decrease the amount that the frontalis muscle has to raise the brows, or surgically with a combination of a Browlift with an upper eyelid incision.

The Browlift with Upper Eyelid Incision Procedure

In many cases if only the eyelid skin is removed, the brow will drop, so Dr. Varkarakis performs a combination of a brow lift with a small incision on one of the lateral sides abut 10cm above the ear and the one on the top of the skull. Both of the incisions are very small and unnoticeable. Once the excess skin is removed, the ligaments from the temporal forehead are detached, they are able to freely mobilize the eyebrow. Once the brow is approximated, the excess skin is removed and some of the fat is repositioned. This will allow the brow to reposition to a more natural state, and remain fixated for longevity.

The Result
The end result is a very natural and produces a very high satisfaction to the patient. Also the patients can usually see better after the procedure. To learn more about this eyebrow lift procedure with Dr. Varkarakis, call the office in Miami, Florida to setup a consultation at 305-853-8333.

The Next Generation "IrisVision 3.0" Launched to Help the Visually Impaired and Legally Blind See Again



Pleasanton, CA, April 16, 2019 IrisVision, a California-based startup, recently released "IrisVision 3.0," an updated version of a revolutionary low vision solution introduced a couple of years ago. This new release, being referred as "The Next Generation IrisVision," packs a handful of innovative solutions, further easing out the visually impaired and the legally blind in seeing the world around them.

Regarded as one of the best and the most comprehensive vision care systems for the visually impaired and legally blind, the best got even better. With the release of IrisVision 3.0, thanks to the collaboration between Dr. Frank Werblin, Chief Scientist and inventor on the project and Ammad Khan, the CEO of a thriving mobile app development company based in Pleasanton, California.

“I’ve been working in the area of vision research and vision restoration for 40 years, most recently as Professor of Neuroscience at UC Berkeley. Much of that work has focused on restoring vision to the blind. But I sensed a need for serving a much larger community of the visually-impaired: those who still have some remaining useful vision,” said Dr. Frank Werblin, talking recently to the "Medgadget," the famed weblog about medical technologies.

He further added, “I teamed up with our CEO Ammad Khan, who at the time was CEO of a very successful mobile app development company in the Bay Area, to develop, refine, and commercialize our wearable low vision aid. Together, Ammad and I are on a mission to bring this innovative technology to the millions of people around the world who might benefit.”

The release of IrisVision 3.0 brings them one step closer to achieving their collective goal of helping millions suffering with low vision conditions, bringing various advanced and user-friendly features to their solution, such as:

IrisVision Assistant: A voice enabled personal assistant, which can be enabled by simply saying “Start Iris,” adding a whole new dimension to going hands free.

IrisReader: A proprietary feature based on advanced OCR techniques, IrisReader reads text to the user straight from a book, document, menu, label or even a newspaper.

Photo Gallery: The Photo gallery is another one of the advanced features showcased in IrisVision 3.0, helping the user take snaps with these electronic glasses on, saving them in the gallery for viewing later.

Video Player: IrisVision 3.0 also includes a video player designed to help users stream their favorite videos while connected to a WiFi, also supporting voice-enabled search.

With the IrisVision 3.0, millions of low vision patients will be able to interact and integrate into their community with added comfort, ease and more independence. The new features showcased not only unlock new and exciting opportunities for the visually impaired but also for practitioners, eye specialists and ophthalmologists to test and stretch the limits of low vision.

IrisVision is an FDA registered Class-I medical device, leveraging a powerful combination of virtual reality technology from Samsung and innovative custom software, developed in collaboration with some of the United States’ leading experts at the Johns Hopkins optical clinic.

University Innovation and Entrepreneurship Showcase on Capitol Hill Spotlights Startup Company AEIOU Scientific Born Out of Federally-Funded Research at Ohio University



AEIOU Scientific, a startup commercializing innovative research conducted at Ohio University, was featured at The University Innovation and Entrepreneurship Showcase April 10 on Capitol Hill. Its noninvasive device is intended to improve diagnosis of osteoporosis. Hosted by the Association of Public and Land-grant Universities and the Association of American Universities, the event spotlights twenty startup companies using federally funded, university-based research.

Washington, DC, April, 2019 AEIOU Scientific, 
a business born of research conducted at Ohio University, was selected through a highly competitive process and was featured at The University Innovation and Entrepreneurship Showcase April 10 on Capitol Hill. Hosted by the Association of Public and Land-grant Universities and the Association of American Universities, the event will spotlight twenty startup companies from across the nation that have created products and services using federally funded, university-based research.

The showcase highlighted the important role of federally funded university research in driving high-value entrepreneurship and the U.S. innovation economy for members of Congress, their staff, and national economic development and innovation policy leaders. Speakers included: U.S. Patent and Trademark Office Director Andrei Iancu; National Institute of Standards and Technology Associate Director for Innovation and Industry Services Phillip Singerman; House Science, Space, and Technology Committee Chair Eddie Bernice Johnson and Ranking Member Frank Lucas; APLU President Peter McPherson; and AAU President Mary Sue Coleman.

AEIOU Scientific (AEIOU) is startup company commercializing Ohio University’s Cortical Bone Mechanics Technology™ (CBMT) to predict the strength of bone in living humans. CBMT is the first non-invasive and radiation-free test to accurately measure ulna bending and make other direct functional measurements of structural mechanical properties of bone in vivo. CBMT has been demonstrated to be significantly more accurate than alternatives such as bone mineral density (BMD) scans in predicting bone strength/fragility in cortical bone studies. AEIOU currently markets a scientific lab instrument for human bone research studies. AEIOU received a $477,000 Phase I SBIR grant from the NIH National Institute on Aging that was essential for technology validation and commercialization. The Company’s SBIR grant is critical now to its development of a CBMT medical device that may improve the diagnosis of osteoporosis (fragility fracture risk), a disease that will affect 44 million Americans at a cost of billions of dollars annually.

Development of the CBMT technology began almost a decade ago, in the laboratory of Anne Loucks, a professor of biological sciences in Ohio University’s College of Arts and Sciences. While conducting research on female athletes who experienced bone fractures, Loucks discovered that existing technologies did not accurately measure or predict bone strength. Federal research funding to her lab was essential to beginning the development of a solution and collection of preliminary data. Then in 2014, the Ohio Musculoskeletal and Neurological Institute provided seed funding to Professor Loucks to support the project. In early 2016, Ohio University’s Innovation Strategy program awarded a team led by Loucks, co-inventor Lyn Bowman of the College of Arts and Sciences, and Brian Clark of the Heritage College of Osteopathic Medicine a $875,000 grant to further develop the patent-pending technology.

“This is a great example of a public-private partnership working,” said AEIOU president and CEO Jeff Spitzner. “Our story would not be happening without the federal research funding to the academic institution to perform the fundamental research and then SBIR funding to support important high-risk early stage commercial R&D that typically does not get funded by the private sector to validate the technology and ready it for market and investment. Federal research funding is not an expense, it is an investment in the future of our country. In this case, a future in which we hope AEIOU will improve the health and quality of life for millions of Americans and save the healthcare system billions of dollars through better targeting of osteoporosis treatment. Furthermore,” said Spitzner, “Ohio University’s commitment to commercialization and the outstanding resources it supports, such as its Innovation Center where AEIOU maintains its lab and offices, makes it an easy choice to grow our company here in Athens, Ohio, where we hope to add new jobs and opportunities to this Appalachian region in Southeast Ohio that needs it – a further benefit of federal and State of Ohio research funding we have received.”

“Path-breaking research is fundamental to the mission of public universities,” said APLU President McPherson. “Strong federal investment in university-based research is essential for our nation because that research provides the foundation for the development of new technologies that save lives, make us more secure, improve our quality of life, and power our economy forward. We’re thrilled to highlight some of the best startups sparked out of that investment to demonstrate how university-based research fuels innovation and entrepreneurship across the country. These startups are examples of why 88 percent of voters agree it’s important for the federal government to fund science and technology research. Scientific research spurs economic growth.”

Of the showcase, AAU President Mary Sue Coleman said: “The partnership between the government and American research universities lies at the heart of the U.S. scientific and higher education enterprise. This unique American partnership has empowered entrepreneurs to start companies and entire new industries that have advanced our health, national security, and economy.”

Startups were chosen by a selection committee comprised of innovation experts who considered the level of student engagement in the startup, the strength of the startup technology, and its connection to research. The committee also factored whether the affiliated university had earned APLU’s Innovation & Economic Prosperity University designation, a national recognition for higher education institutions that have demonstrated a substantial and sustainable commitment to promoting economic development.

In addition to Ohio University and AEIOU Scientific, the following universities and startups participated in the showcase:

KIYATEC (Clemson University)

MicroRid Technologies (Stony Brook University)

TissueForm (University of Colorado-Boulder):

Skylark Wireless (Rice University)

Xallent (Cornell University)

Ferric Contrast (University at Buffalo, SUNY)

Florida Insect Control Group (University of Florida)

Eonix (SUNY Polytechnic Institute)

N-Sense (Iowa State University)

NOWA Innovations (UC-Irvine)

Entrada Therapeutics (Ohio State University)

Lumme (University of Massachusetts, Amherst)

AEIOU Scientific (Ohio University)

Soteria Solutions (University of New Hampshire)

SpotLESS Materials (Penn State University)

Zeno Power (Vanderbilt University)

Magnitude Instruments (Penn State University)

Eco Carbon Tech (Washington State University)

Haptimage (Purdue University)

Roll-2-Roll Technologies (Oklahoma State University)

Manufacture of 3D Printed Titanium Orthopedics Partners with Biomedical Engineering Program



Tangible Solutions, Inc., Contract Manufacturer of 3D Printed Orthopedics Implants for Orthopedic OEMs and Cedarville University’s Biomedical Engineering Program have partnered to further develop 3D printing titanium for Medical Orthopedics.

Dayton, OH, April, 2019 Tangible Solutions, Inc., Contract Manufacturer of 3D Printed Orthopedics Implants for Orthopedic OEMs and Cedarville University’s Biomedical Engineering Program have partnered to further develop 3D printing technology for the Orthopedics industry.

3D Printed Titanium is uniquely positioned due to excellent biocompatibility and pro-cell growth characteristics. The strength, stiffness, corrosion resistance and high strength make 3D Printed Titanium well suited for bone and joint implant applications. This partnership will be among the first in the world working to understand how 3D Printed architecture, structure and surface design characteristics affect the functionality of 3D printed titanium for successful implant design and manufacturing.

A matrix of 3D printed titanium variables will be studied in order to evaluate cell viability outcomes for various 3D printed architectural and surface designs.

“Our customers spend 1000’s of hours engineering the next generation of orthopedic implants. Tangible Solutions’ sole focus is 3D Printing Titanium Orthopedic Implants for OEMs. We aim to use this knowledge to further elevate the high standards of 3D Printed Orthopedics. Furthermore, Cedarville University is an impressive institution and they have a very passionate staff and student body.” -Adam Clark, CEO of Tangible Solutions.

About Tangible Solutions

Tangible Solutions is a Contract Manufacturer of 3D Printed Titanium Orthopedic Implants. The company is registered with the FDA, ISO 13485:2016 and ISO 9001:2015 certified. Founded in 2013, the company serves Orthopedic Implant OEMs who need a supplier focused on the medical device market. Tangible prides itself on providing value beyond 3D Printing with in-house machining, post-processing capabilities, and lifecycle management of Orthopedic Implant Products. Raising the bar of part quality, on-time delivery, and customer service...with a smile.

Perimeter Medical Imaging, Inc. Announces 510(k) Clearance by FDA



Toronto, Canada, April 2019 Perimeter Medical Imaging, Inc. (“Perimeter Medical”) announced today that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the second generation of their platform imaging tool used in the evaluation of human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization.

Enhancements to the newly cleared OTIS™ 2.0 system over the previous generation include:
- A novel specimen positioning consumable feature
- Touchscreen interface with improved software, designed to streamline integration with existing clinical workflow
- 10x faster image acquisition speed

Perimeter has developed a world class proprietary reference atlas, with correlations between OTIS™ images and microstructure features identified in histology for a variety of tissue types, including adrenal glands, breast, cervical, colon, heart, kidney, liver, pancreas, spleen, thyroid, tongue and tonsil tissues. This atlas will be available as a tool to clinicians who are learning about the optical coherence tomography imaging modality.

"Today we announce another significant step forward in our mission to provide the best possible tools for clinicians who are treating cancer patients, as well as our preparation for a commercial launch in 2020," said Andrew Berkeley, co-Founder and VP of Business Development of Perimeter Medical. "Our clinical partners want effective, intuitive surgical tools to improve patient care. By assessing subsurface information in real time, clinicians see the potential for better accuracy in intervention. We will continue to advance the field of OCT imaging and expand applications of the OTIS™ system."

The OTIS™ provides high-resolution, real-time imaging of the margin of an excised tissue specimen, enabling clinicians to visualize sub-surface structures up to 2 mm below the surface, while maintaining the integrity of the specimen for standard of care processing, which typically takes place in the hours or days following the surgical procedure.

New World Resource Corp. ("New World" TSX.V “NW”) and Perimeter Medical have previously announced that they entered into a non-binding letter of intent for the acquisition of all of the issued and outstanding shares of Perimeter Medical by New World in a reverse takeover transaction. This transaction will enable Perimeter to raise the capital needed for a full-scale commercial launch in the US in 2020.

Indications for Use: The OTIS™ 2.0 is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest.

The OTIS™ 2.0: an advanced imaging tool for excised tissue The first-generation of the OTIS™ platform was the first FDA-cleared device to provide automated, rapid collection of Optical Coherence Tomography (OCT) images from an excised specimen. Conventional OCT imaging devices required the clinician-user to move his/her hand to collect "point-by-point" images, increasing operator workload and generating images from a small number of points on the specimen. The OTIS™ platform leverages Perimeter's proprietary Wide-Field Optical Coherence Tomography Imaging technique to overcome this limitation, leading to rapid, intuitive imaging of the entire specimen.

About Perimeter Medical Imaging, Inc.: Perimeter Medical develops, patents, and commercializes advanced in-procedural medical imaging tools. The OTIS™ platform provides clinicians with real-time, ultra-high resolution, sub-surface image volumes of the margin (1-2 mm below the surface) of an excised tissue specimen. The ability to visualize microscopic tissue structures during the clinical procedure has the potential to result in better long-term outcomes for patients and lower costs to the healthcare system. Perimeter Medical was founded in 2013. Investors, led by Roadmap Capital, have invested over C$16 million in Perimeter Medical that was used for product development, clinical research, and obtaining three FDA clearances. Perimeter has also received C$5 million in non-dilutive funding since 2013.

For information with respect to the Company or the contents of this news release, please email [email protected]

Forward Looking Statements: This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward-looking statements include, but are not limited to, statements about Perimeter's financial results and market acceptance of Perimeter's existing products, future products or technology. Words such as "could," "anticipates," "expects," "outlook," "intends," "plans," "believes," "seeks," "vision," "estimates," "may," "will," "future," "horizon," "aiming," "driving," "target" (or variations of them) and similar statements, are forward-looking statements. Forward-looking statements involve risks, uncertainties and assumptions that are difficult to predict and could cause Perimeter's results to differ materially from those presented. These risks, uncertainties and assumptions include, but are not limited to, changes in: the regulatory environment; global economics; trade compliance requirements, duties or tariffs; third-party reimbursement levels; currency exchange rates; taxation, healthcare law, and product clearance requirements, as well as those related to: adverse publicity about Perimeter Medical and our products; our reliance on sole or limited source suppliers; our ability to commercialize our products successfully; the impact of competitive products and pricing. These forward-looking statements are made as of the date of this press release, and Perimeter Medical assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law

Swedish Medical Center Neurologist Explains What to do if You Think You’re Having a Stroke



With stroke door to treatment times averaging just 20 minutes, Swedish serves as the Rocky Mountain Region’s referral center for the most advanced stroke treatment and was the state’s first Joint Commission certified Comprehensive Stroke Center.

Englewood, CO, March, 2019 A stroke can happen to anyone at any time and is a “brain attack,” meaning blood flow to an area of the brain gets cut off. The cells in the affected area of the brain do not get oxygen and start to die off. Abilities controlled by this area of the brain, such as muscle control or memory, can be lost.

As 30,000 brain cells die each second during a stroke, medical personnel needs to intervene as quickly as possible to stop the stroke and limit any damage.

If you think someone is suffering from a stroke, think fast and do the following:

- Face. Ask the person to smile. Does one side of the face droop?
- Arms. Ask the person to raise both arms. Does one arm drift downward? Or is one arm unable to rise up?
- Speech. Ask the person to repeat a simple phrase. Is his or her speech slurred or strange?
- Time. If you observe any of these signs, call 911 immediately.

Although strokes usually occur in people age 65 and up, adults in younger age groups are suffering strokes in increasing numbers. In fact, one in four adults older than 25 is at risk for stroke during his or her lifetime, according to a 25-year study published in December 2018 in the New England Journal of Medicine.

Young people usually exhibit similar stroke symptoms to older adults, but they may not seek treatment as quickly since strokes are considered rare in those under 50. One study found that young people are also more likely to be misdiagnosed in emergency rooms because common symptoms such as headaches, vertigo and nausea may be associated with migraines, intoxication and other conditions.

“The biggest piece of advice I can give is to call 9-1-1 immediately, and let the operator know it’s a stroke,” says Jeff Wagner, MD, a neurosurgeon and the stroke program director at Swedish Medical Center. “As soon as the symptoms start, check the time, so you’re able to tell the medical team. While you wait for the medical team to arrive, lay down flat. Lying flat on the ground may make the symptoms better temporarily and prevent some of the brain from being damaged while you wait.”

Cause and effect

The primary causes of stroke are obesity, diabetes, high blood pressure, smoking and excess alcohol consumption. However, other medical problems are also linked to stroke, including:

- Blood clots or blood clotting abnormalities
- Congenital heart disease
- Family history of stroke
- Drug abuse
- Trauma from whiplash or sports-related activities
- Migraines combined with an aura and/or loss of vision or function on one side
- Hyperthyroidism (overactive thyroid)

There are many steps you can take to prevent stroke, including getting enough exercise, maintaining a healthy diet, and keeping other risk factors under control.

Learn more about Colorado’s first comprehensive stroke center. Visit

Latest Developments in Combating Antifungal Resistance to be Discussed by Industry Leaders at Superbugs & Superdrugs Conference in London



SMi Reports: Superbugs & Superdrugs conference co-chairs have released a letter of invitation for the 21st annual event, taking place on 18th-19th March 2019 in London.

London, United Kingdom, In just under 6 weeks, SMi's 21st Annual Superbugs & Superdrugs Conference will open its doors to big pharmas, academics, and the wider scientific community to explore the challenges and potential solutions to the increasing threat of antibiotic resistance.

This year’s two-day event will provide industry professionals with an in-depth knowledge of the scientific, economic, and regulatory challenges facing the industry.

Attendees will be able to hear from an international gathering of expert speakers sharing their valuable perspectives and experiences in the latest developments in antimicrobial research, novel antifungal agents, funding and regulations, and more.

SMi Group are delighted to welcome a new expert speaker to this year’s conference; Dr Fiona Rudkin, CEO of Myobiologics, who will be presenting on “Immunotherapeutics to Treat Life-Threatening Fungal Infections.”

The 2019 conference is set to explore tactics to fight the growing threat of antifungal resistance with industry leaders Meiji Seika Pharma, SCYNEXIS, and Blueberry Therapeutics.

Excessive use of antifungal agents, coupled with fewer new drugs being developed, is contributing to the accumulation of currently under-recognised multidrug-resistant fungi.

The largely neglected issue is threatening human health, as well as global food security, and without intervention can become extremely difficult to combat in the future.

Kazunori Maebashi, Senior Project Manager at Meiji Seika Pharma will be presenting on "The Development of ME1111 at Meiji Seika," focusing on a novel class of antifungal agent which is under clinical development as a topical onychomycosis treatment.

Fungal diseases are a major public health issue with high mortality rates and limited treatment options. This year's Superbugs & Superdrugs event will address this issue with a series of in-depth presentations from senior experts including David Cook, Chief Scientific Officer at Blueberry Therapeutics speaking about “Developing New Therapies for Fungal Infection,” as well as Stephen Barat, Head of Pre-Clinical & Early Clinical Development at SCYNEXIS speaking about “Activity of Ibrexafungerp in Murine Models of Pneumocystis Pneumonia”

In addition, there are two interactive workshops on 20th March, which will be hosted by industry experts focusing on two key areas, including: “Understanding the complexity of the microbiome and how to navigate it” led by Case Western Reserve University & FairyGut Mother, and “Understanding PK/PD in antimicrobial research” led by University of Liverpool.

Download the latest brochure on the event website at:

Superbugs & Superdrugs Conference
18th-19th March 2019
London, UK

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Vascular Care Leaders Underscore PAD Risks for Americans Living with Kidney Disease on World Kidney Day



Americans with CKD are at a higher risk than the general population of developing PAD.

Washington, DC, March, 2019  
The CardioVascular Coalition (CVC), a coalition of cardiovascular and endovascular care providers, physicians, and manufacturers created to improve awareness, prevention, and intervention of vascular disease, is urging increased understanding for kidney health and related health conditions, including Peripheral Artery Disease (PAD), in recognition of World Kidney Day.

Chronic Kidney Disease (CKD) is the ninth leading cause of death in the United States affecting an estimated 26 million Americans. Research has shown that Americans with CKD are at a higher risk than the general population of developing PAD, which causes narrowing or blockage of the vessels that carry blood from the heart to the legs. Studies have also shown patients with CKD are less likely to be provided recommended "optimal" PAD care.

PAD is a circulatory condition affecting as many as 18 million Americans. Like CKD, PAD disproportionately impacts minority communities due to the higher prevalence of diabetes and other risk factors. If not properly managed, PAD can lead to non-traumatic lower limb amputations, which data show lead to lower quality of life, increased risk for death and higher healthcare costs.

“Public policies are needed to increase access to PAD diagnosis and intervention, particularly among older Americans dependent on Medicare to access care, and who are often living with multiple comorbidities common across this patient population including diabetes and hypertension,” said Dr. Neil Marwah of National Cardiovascular Partners. “Other important factors impacting both CKD and PAD patient groups are the racial disparities that exist, which show African Americans are at a measurably higher risk for both diseases conditions.”

In fact, data show in regions with larger populations of African Americans living with diabetes, the PAD-related amputation risks are as much as three to four times higher than the national average. Nationally, the amputation rate among African American Medicare patients is nearly three times higher than the rate among other beneficiaries.

The CardioVascular Coalition has been working with the PAD Task Force to advance a comprehensive strategy that combines increased public awareness and robust screening with non-amputation treatment measures and multidisciplinary care. The PAD Task Force has called on the Administration to convene an intragovernmental workgroup to develop a standardized model for amputation reduction.

The CardioVascular Coalition (CVC) is comprised of national organizations representing physicians, care providers, advocates, and manufacturers who came together to advance community-based solutions designed to improve awareness and prevention of cardiovascular disease and peripheral artery disease, reduce geographic disparities in access to care, and secure patient access to high-quality, cost-effective, community-based interventional treatment across America. Learn more at



Jenny Angel

Health & Medicine News Reports

Global News Aruba

The immune system is known as the body defense mechanism.  It performs an outstanding job 

by fighting against disease-causing microorganisms. However, there are some of the times that 

the immune system failed in carrying out its defense functions. During this time, disease-causing organism penetrates without hindrance and results in sickness in susceptible individuals. The good news is that there are so many things that can be done to get involved in this process and strengthen your immune system. The main aim of this articles centers on what you can do to keep your immune system strong.

1. Sleep well at night and put stress under control. When you are deprived of sleep and there is too much stress, this result in an increase in the level of the hormone cortisol, and when it is left uncontrolled, it can thwart the functioning of the immune system.

2. Do not smoke tobacco. Smoking of tobacco weakens the immune defenses and increases the risk of bronchitis and pneumonia in all individuals and middle ear infections in children.

3. Reduce your alcohol consumption. Too much of alcohol damages the immune system and increases the rate at which affected individual becomes susceptible to lung infections.

4. Eat lots of vegetables. Vegetables, fruits, nuts and seeds that will give your body the nutrients your immune system needs are needed to boost the function of the immune system. According to a study carried out on adults, it was revealed that increasing the consumption of fruit and vegetables improves antibody response to Pneumovax vaccine, which guides against Streptococcus pneumonia.

5. Put probiotics into consideration. A lot of findings have revealed that supplements reduce the frequency of respiratory and gastrointestinal infections. It has also been shown that fermented dairy products reduce respiratory infections in adults and children.

6. Exercise

A lot of people engage in physical exercise for the purpose of getting in shape, but contrary to this, exercise also performs some other important roles such as increasing the function of the immune system, improves the quality of sleep and strengthens our body. In the event that there is no medical problem that prevents you from exercise, find time for a workout, even if it's a long walk!

7. Make use of garlic.

Garlic is a plant which is popular for its antibacterial, antiviral, antifungal and immunological effects. Garlic stimulates the production of white blood cells and increases the rate at which the antibody is produced. The ability of garlic to boost the immune system rest on the presence of sulfur; garlic also functions as an antioxidant which helps to limit the accumulation of free radicals in the bloodstream.

8. Mushroom: Mushrooms contains a high amount of antioxidants and it also contains lots of selenium. Mushrooms are also known for their antiviral, antibacterial and anti-tumor effects. There are many types of mushrooms but the white mushrooms have a stimulating effect on the immune system more than others such as oysters and shiitake. According to a recent study, it has been shown that a concentrated extract of shiitake enhances the immune function in women with breast cancer.

9. Make use of immune-supportive herbs. In the event that you have intermittent infections, consider taking plants that support the immune system, such as eleuthero (Eleutherococcus senticocus), Asian ginseng (Panax ginseng), American Ginseng (Panax quinquefolius) and Astragalus (A. membranaceus).

10. Make Echinacea Tincture. It's a good thing to have when respiratory viruses overwhelm your defenses.

Consuming the types of foods and lifestyle changes stated in this article can strengthen the immune systems and enable them to better fight against infections. It is important to understand the fact that the immune system is complex. As mentioned above a healthy balanced diet is just one way to boost immune health.

It is also important to keep in mind other life-related factors that can affect the health of the immune system, such as physical activity, and not smoking.

Make sure you get in touch with your doctor on the off chance that you have persistent colds or some other illnesses and when you are also worried about your immune system.

Reproduction of this material is strictly prohibited without permission

Read at your own discretion.

Jenny Angel Staff News Reporter

Norberto Tjon Ajong Editor in Chief